To advance India’s precision oncology and equitable access to molecular diagnostics, Servier India, a subsidiary of the France-based Servier Group, has announced a strategic partnership with MedGenome and Strand Life Sciences to launch a patient-centric biomarker testing initiative across India. The program aims to improve diagnostic access for patients with IDH-mutated Acute Myeloid Leukaemia (AML)—an aggressive blood cancer—and Cholangiocarcinoma (CCA), a rare bile duct cancer.

As part of this initiative, customised panels for key biomarkers, including IDH1 and IDH2 mutations, will be made available to healthcare professionals across both public and private sectors. Importantly, these tests will be offered free of cost in the government sector and at subsidised rates in private institutions, helping to make advanced molecular testing more affordable and accessible nationwide.

“Access to timely and precise diagnosis should never depend on geography or financial status,” said Aurelien Breton, Managing Director, Servier India. “For cancers like AML and CCA, molecular testing is vital to inform treatment decisions and improve survival outcomes. This collaboration underscores our commitment to closing the diagnostic gap by bringing advanced biomarker testing closer to patients across India.”

Emphasising the clinical importance of the initiative, Pratima Tripathi, Commercial Director – Oncology, Servier India, added, “Precision oncology begins with precision diagnosis. Identifying key genetic mutations is fundamental in guiding treatment decisions for AML and Cholangiocarcinoma. By enabling wider access to such testing, we are empowering clinicians to make informed, evidence-based treatment choices and improving patient outcomes.”

Highlighting the implementation focus, Aliasgar Patanwala, Market Access Lead, Servier India, noted, “True access is achieved through collaboration. This initiative strengthens the coordination between laboratories, clinicians, and patient pathways—ensuring diagnostic insights translate into timely, actionable care.”

The biomarker testing initiative is part of ‘Servier Care’, Servier India’s patient support program that provides holistic assistance to eligible patients, including financial aid, free drug support, and subsidised diagnostics—ensuring continuous, compassionate care throughout the treatment journey.

With this collaboration, Servier India reinforces its mission to advance precision-driven, patient-centric, and equitable healthcare in the country.

With a strong presence in India for nearly four decades, Servier India is an innovative healthcare company dedicated to transforming lives through high-quality medicines that address evolving patient needs. The company’s portfolio focuses on key therapeutic areas, including cardiometabolism, venous diseases, and oncology.

Also read: Bessemer Backs Pluro Fertility’s $14M Series A to Redefine IVF Care in India

Globally, the Servier Group is an independent, foundation-governed pharmaceutical organisation headquartered in France, operating in nearly 140 countries. A global leader in cardiometabolism and venous diseases, Servier is also expanding rapidly in oncology, particularly in the treatment of rare cancers. Guided by a mission to deliver therapeutic progress for patients, Servier invests heavily in research and development, with a 2024 global revenue of €5.9 billion reflecting its commitment to innovation and long-term healthcare impact.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!